Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 17 Alpha-allyl-17-beta-hydroxyestra-4,9,11-trien-3-one
2. 17 Alpha-allyl-estratriene 4,9,11,17 Beta-ol-one
3. 17-allyltrenbolone
4. Allyl Trenbolone
5. Regumate
6. Ru-2267
1. 850-52-2
2. Allyltrenbolone
3. Regumate
4. Allyl Trenbolone
5. Ru-2267
6. A-35957
7. 2u0x0ja2nb
8. Estra-4,9,11-trien-3-one, 17-hydroxy-17-(2-propenyl)-, (17b)-
9. Nsc-759180
10. 17-alpha-allyl-estratriene-4,9,11,17-beta-ol-3-one
11. Dsstox_cid_28789
12. Dsstox_rid_83058
13. Dsstox_gsid_48863
14. (8s,13s,14s,17r)-17-allyl-17-hydroxy-13-methyl-1,2,6,7,8,13,14,15,16,17-decahydro-3h-cyclopenta[a]phenanthren-3-one
15. (8s,13s,14s,17r)-17-hydroxy-13-methyl-17-prop-2-enyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
16. Altrenogestum
17. (17beta)-17-hydroxy-17-(2-propenyl)estra-4,9,11-trien-3-one
18. Cas-850-52-2
19. Regu-mate
20. Drc 6246
21. Unii-2u0x0ja2nb
22. Altrenogestum [inn-latin]
23. Ru 2267
24. Altrenogestrel
25. Altrenogest [usan:inn:ban]
26. R 2267
27. Ncgc00183119-01
28. A 35957
29. Einecs 212-703-1
30. Altrenogest [mi]
31. Altrenogest [inn]
32. Altrenogest (usan/inn)
33. Altrenogest [usan]
34. Altrenogest [mart.]
35. Schembl140056
36. 17alpha-allyl-17-hydroxyestra-4,9,11-trien-3-one
37. Altrenogest [green Book]
38. Chembl1315492
39. Dtxsid3048863
40. Chebi:191255
41. Hms3715d18
42. Bcp13100
43. Drc-6246
44. Estra-4,9,11-trien-3-one, 17beta-hydroxy-17-(2-propenyl)-
45. Hy-b0521
46. Zinc4214784
47. Tox21_113356
48. Mfcd00867855
49. Ru2267
50. S3167
51. Akos025310098
52. Estra-4,9,11-trien-3-one, 17-hydroxy-17-(2-propen-1-yl)-, (17beta)-
53. Estra-4,9,11-trien-3-one, 17-hydroxy-17-(2-propenyl)-, (17-beta)-
54. Tox21_113356_1
55. Ccg-221218
56. Db11372
57. Nsc 759180
58. Rh-2267
59. Ncgc00166309-01
60. Ncgc00166309-02
61. As-12848
62. Altrenogest 100 Microg/ml In Acetonitrile
63. A35957;allyltrenbolone;r2267;ru2267
64. B1503
65. R2267
66. A35957
67. D02840
68. Ab01566827_01
69. Altrenogest, Vetranal(tm), Analytical Standard
70. 850a522
71. A841082
72. Q-101420
73. Q4736979
74. (17?)-17-allyl-17-hydroxyestra-4,9,11-trien-3-one
75. 17-alpha-allyl-17-beta-hydroxyestra-4,9,11-trien-3-one
76. 17.alpha.-allyl-17-hydroxyestra-4,9,11-trien-3-one
77. Estra-4,9,11-trien-3-one, 17-alpha-allyl-17-hydroxy-
78. 17.alpha.-allyl-estra-4,9,11-triene-17.beta.-ol-3-one
79. Estra-4,9,11-trien-3-one, 17.beta.-hydroxy-17-(2-propenyl)-
80. Estra-4,9,11-trien-3-one, 17-hydroxy-17-(2-propen-1-yl)-, (17.beta.)-
81. (8s,13r,14s,17r)-17-hydroxy-13-methyl-17-prop-2-enyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
82. (8s,13s,14s,17r)-17-allyl-17-hydroxy-13-methyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one;altrenogest
Molecular Weight | 310.4 g/mol |
---|---|
Molecular Formula | C21H26O2 |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 2 |
Exact Mass | 310.193280068 g/mol |
Monoisotopic Mass | 310.193280068 g/mol |
Topological Polar Surface Area | 37.3 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 665 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Progestins
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY. (See all compounds classified as Progestins.)
Market Place
ABOUT THIS PAGE
A Altrenogest manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Altrenogest, including repackagers and relabelers. The FDA regulates Altrenogest manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Altrenogest API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Altrenogest manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Altrenogest supplier is an individual or a company that provides Altrenogest active pharmaceutical ingredient (API) or Altrenogest finished formulations upon request. The Altrenogest suppliers may include Altrenogest API manufacturers, exporters, distributors and traders.
click here to find a list of Altrenogest suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Altrenogest DMF (Drug Master File) is a document detailing the whole manufacturing process of Altrenogest active pharmaceutical ingredient (API) in detail. Different forms of Altrenogest DMFs exist exist since differing nations have different regulations, such as Altrenogest USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Altrenogest DMF submitted to regulatory agencies in the US is known as a USDMF. Altrenogest USDMF includes data on Altrenogest's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Altrenogest USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Altrenogest suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Altrenogest as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Altrenogest API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Altrenogest as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Altrenogest and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Altrenogest NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Altrenogest suppliers with NDC on PharmaCompass.
Altrenogest Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Altrenogest GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Altrenogest GMP manufacturer or Altrenogest GMP API supplier for your needs.
A Altrenogest CoA (Certificate of Analysis) is a formal document that attests to Altrenogest's compliance with Altrenogest specifications and serves as a tool for batch-level quality control.
Altrenogest CoA mostly includes findings from lab analyses of a specific batch. For each Altrenogest CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Altrenogest may be tested according to a variety of international standards, such as European Pharmacopoeia (Altrenogest EP), Altrenogest JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Altrenogest USP).
LOOKING FOR A SUPPLIER?